Cancer drug combo trial halted early after enrolling only 2 patients

NCT ID NCT06939036

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 31 times

Summary

This study tested a new radioactive drug (225Ac-SSO110) combined with standard treatments for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to find a safe dose and see if the drug shrank tumors. However, the trial was stopped early after enrolling only 2 participants, so no clear results are available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Biogenix Molecular

    Miami, Florida, 33165, United States

  • GenesisCare

    Alexandria, Australia

  • John Theurer Cancer Center at Hackensack UMC

    Hackensack, New Jersey, 07601, United States

  • UPMC

    Pittsburgh, Pennsylvania, 15219, United States

  • United Theranostics

    Glen Burnie, Maryland, 21061, United States

  • University of Louisville Health-Brown Cancer Center

    Louisville, Kentucky, 40202, United States

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.